tions as a crucial caveolar component to regulate cardiac function.
CAVEOLAE are plasma membrane invaginations with a flaskshaped morphology that have been implicated in many cellular processes, including signal transduction, endocytosis, transcytosis, and lipid regulation (9, 24) . In the heart, caveolae are abundantly present in ventricular, atrial, and nodal cells (1) and have been shown to be important for colocalization of receptors with their signaling partners (26) . In cardiomyocytes, caveolin-3 (Cav3), a muscle-specific caveolin family member, is a key determinant of caveolar morphology because genetic deletion of Cav3 shows loss of caveolae in cardiac and skeletal myocytes (5, 35) . Cav3 knockout (KO) mice show systolic dysfunction accompanied by cardiac hypertrophy (35) . Mutations in the Cav3 gene have been identified in patients with not only muscular dystrophies but also hypertrophic cardiomyopathy and long QT syndrome (12, 21, 32, 33) . Thus, Cav3 regulates caveolar morphology in cardiomyocytes and cardiac function.
Characterizations of polymerase I and transcript release factor (PTRF)/cavin-1 and subsequently other cavin family members, serum deprivation protein response (SDPR)/cavin-2 and SDR-related gene product that binds to C kinase (SRBC)/ cavin-3, in caveolar morphology have provided further insights into the complexity of the biogenesis of caveolae (3, 8, 13, 14, 18, 20) . PTRF/cavin-1 and SDPR/cavin-2 are expressed in a variety of cell types, including myocytes (2, 6, 10, 11, 14, 18) . SRBC/cavin-3 is expressed in many cell types but not muscle cells per se, despite its expression in the heart and skeletal muscle (10, 20) . Recent studies have revealed that PTRF/ cavin-1 and SDPR/cavin-2 are required for caveolar formation and SRBC/cavin-3 is required for trafficking of caveolar vesicles (8, 10, 14, 18, 20) . Homozygous mutations in the PTRF/ cavin-1 gene have been identified in patients who presented with both generalized lipodystrophy and muscular dystrophy (13) . Furthermore, in patients with congenital generalized lipodystrophy with muscle rippling type 4 who have homozygous PTRF/cavin-1 mutations, long QT syndrome and fatal cardiac arrhythmia have been observed (25, 28) . We have previously identified muscle-restricted coiled-coil protein (MURC), which is expressed in cardiomyocytes, smooth muscle cells, and skeletal myocytes (23) . MURC is also referred to as cavin-4 based on its sequence homology with PTRF/cavin-1 and its localization to caveolae (2, 9) . We have shown that MURC/ cavin-4 is capable of forming complexes with Cav3, PTRF/ cavin-1, and SDPR/cavin-2 and that MURC/cavin-4 overexpression in cardiomyocytes distends caveolae, although MURC/cavin-4 is dispensable for caveola formation (22) .
MURC/cavin-4 deficiency attenuates cardiac hypertrophy induced by ␣ 1 -adrenergic receptor stimulation (22) . Furthermore, we identified MURC/cavin-4 mutations in patients with dilated cardiomyopathy (27) .
The coiled-coil domain has been shown to be responsible for the oligomerization of proteins, and proteins containing its domain exhibit a large diversity of functions, such as gene regulation, cell division, membrane fusion, and drug extrusion (4, 19) . Although MURC/cavin-4 has the coiled-coil domain (human: 44 -77 amino acids and mouse: 44 -77 amino acids), its functional significance is not well known. In the present study, we sought to identify the roles of the coiled-coil domain in MURC/cavin-4 in targeting to caveolae of cardiomyocytes and cardiac function.
MATERIALS AND METHODS

Materials.
Rat monoclonal anti-hemagglutinin (HA) antibody (catalog no. 11867423001) was from Roche Diagnostics. Mouse monoclonal anti-FLAG (catalog no. F3166), anti-␣-actinin (catalog no. A7811), and anti-pan-cadherin (catalog no. C1821) antibodies were from Sigma-Aldrich. Mouse monoclonal anti-T7 antibody (catalog no. 69522) was from Novagen Biosciences, anti-Cav3 antibody (catalog no. 610420) was from BD Transduction Laboratories, anti-Na ϩ -K ϩ -ATPase-␣1 antibody (catalog no. sc-21712) was from Santa Cruz Biotechnology, and anti-GAPDH antibody (catalog no. MAB374) was from Merck Millipore. Rabbit polyclonal anti-PTRF/cavin-1 antibody (catalog no. ab48824) was from Abcam. Rabbit polyclonal anti-phosphorylated (p)ERK1/2 (catalog no. 9101S) and anti-ERK (catalog no. 9102S) antibodies were from Cell Signaling Technology. Horseradish peroxidase-conjugated mouse monoclonal anti-glutathione-S-transferase (GST) antibody (catalog no. 011-21891) was from Wako Pure Chemical Industries. Rabbit polyclonal anti-MURC/ cavin-4 antibody was generated as previously described (23, 29) . pEGFP-N3 vector was purchased from Clontech. H9c2 cells were purchased from the American Type Culture Collection. The adenovirus expression vector kit (Dual Version) was from Takara Bio. Human Cav3-expressing vector (pcDNA3.1-hCav3-T7) was kindly provided by Yukiko K. Hayashi (Tokyo Medical University, Tokyo, Japan) (13) . Other materials were obtained from commercial sources.
Plasmid construction. The corresponding cDNA fragment for mouse (m)MURC/cavin-4 with a COOH-terminal HA epitope was obtained by PCR with pcDNA3-mMURC-FLAG (23) as a template with the following primers: mMURC forward primer 5=-CACCATG-GAACACAACGGATCAGCTT-3= and mMURC-HA reverse primer 5=-CTAAGCGTAATCTGGAACATCGTATGGGTATGAGGACT-GCTTTAGCTCCAACAGGAG-3=. The HA-tagged mMURC fragment was inserted into pcDNA3 (Invitrogen) to generate pcDNA3-mMURC-HA. Deletion mutants lacking the coiled-coil domain of human (h)MURC/cavin-4 and mMURC with a COOH-terminal FLAG or HA epitope (h⌬CC-FLAG, h⌬CC-HA, m⌬CC-FLAG, and m⌬CC-HA) were obtained using a Quikchange II site-directed mutagenesis kit (Stratagene) with pcDNA3.1-hMURC-FLAG (27), pcDNA3.1-hMURC-HA (22), pcDNA3-mMURC-FLAG, and pcDNA3-mMURC-HA as templates, respectively, with the following primers: h⌬CC, forward primer 5=-TGGACAAAGTAGCCTC-CATCTCGCATAGCAATACAGGGCA-3= and reverse primer 5=-TGCCCTGTATTGCTATGCGAGATGGAGGCTACTTTGTCC-3=; and m⌬CC, forward primer 5=-TGGACAGAGTGGCCAGTGTCT-CACACAGCAATACGGGCTA-3= and reverse primer 5=-TAGC-CCGTATTGCTGTGTGAGACACTGGCCACTCTGTCCA-3=. The cDNA fragments of h⌬CC-FLAG, h⌬CC-HA, m⌬CC-FLAG, and m⌬CC-HA were replaced with hMURC-FLAG, hMURC-HA, and mMURC-FLAG fragments to generate pcDNA3.1-h⌬CC-FLAG, pcDNA3.1-h⌬CC-HA, pcDNA3-m⌬CC-FLAG, and pcDNA3-m⌬CC-HA, respectively. The corresponding cDNA fragments for hMURC and h⌬CC without a stop codon were cloned by PCR with pcDNA3.1-hMURC-FLAG and pcDNA3.1-h⌬CC-FLAG as templates with the following primers: hMURC, forward primer-2 5=-AACCGCTAGCATGGAACATAATGGGTCTGC-3= and reverse primer 5=-GGCCGGATCCCGATGAGTGCTTTAAATCTA-3=. The cDNA fragments encoding hMURC and h⌬CC without a stop codon were cloned into the NheI-BamHI site of pEGFP-N3 to generate pEGFP-hMURC and pEGFP-h⌬CC, respectively. The Cav3 fragment from pcDNA3.1-hCav3-T7 was inserted into pGEX-6P-2 (GE Healthcare) to generate pGEX-hCav3. All of the PCR fragments were confirmed by DNA sequencing.
Transfection. H9c2 cells were plated in two-well culture plates. The following day, cells were transfected with 1.0 g of an expression vector containing hMURC-enhanced green fluorescent protein (EGFP) or h⌬CC-EGFP using Lipofectamine LTX (Invitrogen). Cells were cultured for another 72 h and then fixed for fluorescence microscopy.
Confocal immunofluorescence microscopy. Specimens were fixed with 4% paraformaldehyde and stained with anti-Cav3, anti-␣-actinin, and MURC/cavin-4 antibodies. Secondary antibodies were conjugated with Alexa fluor 488 or 555 (Invitrogen), and nuclei were visualized using 4=,6-diamino-2-phenylindole (Invitrogen).
Preparation of cytosolic and membrane fractions. Cell fractionation was performed as previously described (16, 22) . In brief, cells were harvested from 100-mm culture dishes and resuspended in ice-cold homogenization buffer containing 250 mM sucrose, 20 mM phosphate buffer (pH 6.8), and a protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific). Cells were homogenized gently on ice using a Dounce tissue grinder (Sigma-Aldrich) and centrifuged at 1,000 g for 10 min to remove nuclei and remaining cells. Supernatants were ultracentrifuged at 55,000 rpm for 30 min using an Optima TLX centrifuge (Beckman Coulter) with a TLA-100.3 rotor. Supernatants were obtained as the cytosolic fraction. Pellets were lysed with lysis buffer and centrifuged, and supernatants were obtained as the membrane fraction. Because pan-cadherin and Na ϩ -K ϩ -ATPase are markers for the membrane fraction and GAPDH is a marker for the cytosolic fraction (36, 37) , anti-pan-cadherin, anti-Na ϩ -K ϩ -ATPase-␣1, and anti-GAPDH antibodies were used to verify the purity of membrane and cytosolic fractions.
Immunoprecipitation. COS cells were plated in 60-mm dishes. The following day, cells were transfected with pcDNA3.1-hCav3-T7 and either pcDNA3-mMURC-HA or pcDNA3-m⌬CC-HA. The total plasmid amount was adjusted with an empty vector plasmid. Cells were cultured for another 48 h and then lysed with lysis buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 50 mM EDTA, 1% Triton X-100, 60 mM octyl glucoside (Dojindo, Kumamoto, Japan), 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4, and 1ϫ protease inhibitor (Pierce). Cell lysates were incubated with anti-HA or anti-T7 antibodies and subsequently with protein A-Sepharose beads (GE Healthcare) at 4°C overnight. After the beads had been extensively washed with lysis buffer, the bound proteins were eluted by boiling the beads in SDS sample buffer and subjected to SDS-PAGE followed by Western blot analysis.
Western blot analysis. Total cell lysates or fractionated lysates were electrophoresed in SDS-PAGE gels and transferred to polyvinylidene difluoride membranes (Millipore). Membranes were subsequently incubated with primary antibodies against HA, GAPDH, pan-cadherin, FLAG, Cav3, PTRF/cavin-1, Na ϩ -K ϩ -ATPase-␣1, pERK1/2, ERK1/2, and MURC/cavin-4. Horseradish peroxidase-conjugated anti-rat IgG, anti-mouse IgG, and anti-rabbit IgG antibodies (GE Healthcare) were used as secondary antibodies. For immunoblot analysis of GST, peroxidase-conjugated anti-GST antibody was used. Signal intensities were measured using ImageJ software (National Institutes of Health).
GST pulldown assay. Two micrograms of GST-Cav3 were bound to glutathione-Sepharose beads. Beads were incubated with lysates from COS cells transfected with pcDNA3-mMURC-FLAG or pcDNA3-m⌬CC-FLAG for 2 h at room temperature. Sepharose beads alone were used as a control. Beads were washed five times, and proteins were eluted for Western blot analysis.
Primary cardiomyocyte culture. Rat neonatal cardiomyocytes, cultured from 1-day-old Wistar rats, were prepared as previously described with slight modifications (23, 31) . Briefly, ventricles were digested enzymatically, and cardiomyocytes were purified over a Percoll gradient. The culture medium was changed to serum-free medium after 24 h.
Replication-defective recombinant adenoviruses and gene transfer. cDNA encoding h⌬CC-FLAG was inserted into a pAxCAwtit2 cosmid vector in an adenovirus expression vector kit (Dual Version). A recombinant adenovirus expressing h⌬CC1-FLAG (Ad-⌬CC) was generated as previously described (23, 27) . A recombinant adenovirus expressing hMURC-FLAG (Ad-MURC) was constructed as previously described (27) . Ad-LacZ was used as a control, as previously described (23, 27) . Twenty-four hours after being seeded, cardiomyocytes were infected with Ad-LacZ, Ad-MURC, or Ad-⌬CC and incubated at 37°C for 1 h. The viral suspension was removed, and cardiomyocytes were cultured with serum-depleted culture media. Expression of mRNA and protein was examined in cardiomyocytes infected with recombinant adenoviruses for 48 and 72 h, respectively.
Measurement of the cardiomyocyte surface. Cardiomyocytes infected with Ad-LacZ, Ad-MURC, or Ad-⌬CC were fixed with 4% paraformaldehyde, and cells were stained with mouse monoclonal anti-␣-actinin antibody, Alexa fluor 488, and 4=,6-diamino-2-phenylindole. Cells were imaged using an immunofluorescence microscope and measured using ImageJ software (National Institutes of Health). At least 100 cells were measured per sample.
RNA extraction and quantitative RT-PCR. Total RNA was extracted from cells or tissues using an RNeasy Mini kit (Qiagen) or TRIzol reagent (Invitrogen) and then treated with DNase I (Qiagen) to remove any residual DNA. Total RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Synthesized cDNA was analyzed by kinetic real-time PCR using Takara PCR Thermal Cycler Dice (Takara Bio) with Platinum SYBR Green qPCR Super Mix (Invitrogen) as previously described (23, 29) . The primers used were as follows: mouse atrial natriuretic peptide (ANP; Nppa), forward primer 5=-AACCTGCTAGACCAC-CTGGA-3= and reverse primer 5=-TGCTTTTCAAGAGGGCAGAT-3=; mouse brain natriuretic peptide (BNP; Nppb), forward primer 5=-CTGAAGGTGCTGTCCCAGAT-3= and reverse primer 5=-CCT-TGGTCCTTCAAGAGCTG-3=; mouse Gapdh, forward primer 5=-TTGTGATGGGTGTGAACCACGAGA-3= and reverse primer 5=-CATGAGCCCTTCCACAATGCCAAA-3=; rat ANP, forward primer 5=-ATACAGTGCGGTGTCCAACA-3= and reverse primer 5=-CGAGAGCACCTCCATCTCTC-3=; rat BNP, forward primer 5=-GGAAATGGCTCAGAGACAGC-3= and reverse primer 5=-CGATC-CGGTCTATCTTCTGC-3=; rat ␣-myosin heavy chain (␣-MHC; Myh6), forward primer 5=-TGATGACTCCGAGGAGCTTT-3= and reverse primer 5=-TGACACAGACCCTTGAGCAG-3=; rat ␤-MHC (Myh7), forward primer 5=-GGAGCTCACCTACCAGACAGA-3= and reverse primer 5=-CTCAGGGCTTCACAGGCATCC-3=; rat skeletal ␣-actin (SkA; Acta1), forward primer 5=-CACGGCA TTATCACCAACTG-3= and reverse primer 5=-CCGGAG-GCATAGAGAGACAG-3=; rat Cav3, forward primer 5=-GGT-GAACAGAGACCCCAAGA-3= and reverse primer 5=-GGAGACGGTGAAAGTGGTGT-3=; rat Ptrf/cavin-1, forward primer 5=-GCCAGAGGATGAAGTTGGAG-3= and reverse primer 5=-GCTGCTTCAGAGCCTTTACG-3=; and rat Gapdh, forward primer 5=-ATGGGAAGCTGGTCATCAAC-3= and reverse primer 5=-GTGGTTCACACCCATCACAA-3=.
Animals. Transgenic mice expressing m⌬CC-FLAG in the heart (⌬CC-Tg mice) were generated as previously described (23) . Briefly, cDNA encoding m⌬CC-FLAG was cloned into the third 5=-untranslated exon of ␣-MHC promoter plasmid clone 26 (a generous gift from Jeffrey Robbins, Cincinnati Children's Hospital Medical Center, Cincinnati, OH). Experiments were performed on ⌬CC-Tg mice and sex-, strain-, and age-matched nontransgenic (NTg) control mice (C57BL/6 background). All of the aspects of animal care and experimentation performed in this study were approved by the Institutional Animal Care and Use Committee of Kyoto Prefectural University of Medicine.
Echocardiography and morphometric analysis. Echocardiographic analysis of mice was performed as previously described (23) . Briefly, after mice had been anesthetized with 2,2,2-tribromoethanol (0.20 mg/g, Sigma-Aldrich), echocardiography was performed using SO-NOS 5500 (Hewlett-Packard) equipped with a 15-MHz microprobe. After echocardiography, mice were euthanized by cervical dislocation and then weighed. Hearts were excised, rinsed in PBS, and weighed. Body weight or left tibial length was measured to normalize heart weight.
Histological analysis. Cardiac perfusion-fixation was performed using 4% paraformaldehyde and PBS. Hearts were cut into sections, and paraffin-embedded sections of 3 m thick were stained with hematoxylin and eosin or Masson's trichrome. Frozen specimens for immunostaining were cut into 10-m-thick sections. Cross-sectional areas of cardiomyocytes were measured in heart sections stained with hematoxylin and eosin using ImageJ software (National Institutes of Health).
Transmission electron microscopy and quantitation. Transmission electron microscopy was performed as previously described (22) . Briefly, 12-wk-old mouse hearts were fixed with 2% glutaraldehyde in 0.1 M cacodylate buffer, postfixed with 2% OsO 4, and stained with uranyl acetate and lead citrate. The thickness of the sections for transmission electron microscopy was ϳ80 nm. Microtome sections were examined under a H-7100 transmission electron microscope (Hitachi) and photographed at magnifications of ϫ5,000 and ϫ20,000. Caveolae were identified by their characteristic ⍀-shaped membrane profiles open at the cell surface. The depths of caveolae were measured from the caveolar orifice to their bottom in electron micrographs.
Statistical analysis. All experiments were performed at least three times. Data are expressed as means Ϯ SE and were analyzed by Student's t-test for comparisons between two groups or one-way ANOVA followed by a Tukey-Kramer test for multiple comparisons. P values of Ͻ0.05 were considered significant.
RESULTS
Requirement of the coiled-coil domain in MURC/cavin-4 for plasma membrane targeting.
To investigate the function of the coiled-coil domain in MURC/cavin-4 in cardiomyocytes, we generated ⌬CC, a human MURC/cavin-4 mutant lacking the coiled-coil domain. An expression vector expressing EGFPtagged full-length human MURC/cavin-4 or human ⌬CC was transduced into H9c2 cells, a permanent cell line derived from rat cardiac tissue (22) . Fluorescence microscopy revealed that full-length human MURC/cavin-4-EGFP was colocalized with Cav3 at the plasma membrane of H9c2 cells, whereas human ⌬CC-EGFP was not localized to the plasma membrane but distributed to the cytoplasm (Fig. 1A) . Additionally, Cav3 staining was not observed at the plasma membrane of H9c2 cells expressing human ⌬CC-EGFP. However, in H9c2 cells that were not transduced with human ⌬CC-EGFP, Cav3 staining was observed at the plasma membrane. To further examine localization of human ⌬CC, cell fractionation experiments were performed using human embryonic kidney-293 cells. Full-length human MURC/cavin-4 was mainly detected in the membrane fraction, but almost all human ⌬CC was detected in the cytosolic fraction (Fig. 1B) . Thus, the coiled-coil domain in MURC/cavin-4 is critical for targeting MURC/cavin-4 to the plasma membrane in cardiomyocytes.
To assess whether ⌬CC is capable of associating with Cav3, we performed immunoprecipitation using expression vectors expressing Cav3-T7, ⌬CC-HA, and full-length MURC/cavin-4-HA. ⌬CC was associated with Cav3, although its association was less than that of full-length MURC/cavin-4 with Cav3 (Fig. 1C) . Additionally, we performed a GST pulldown assay to assess the association of Cav3 with full-length MURC/ cavin-4 and ⌬CC. The GST pulldown assay showed that full-length MURC/cavin-4 as well as ⌬CC was associated with Cav3 (Fig. 1D) .
Reduced Cav3 protein level induced by ⌬CC in cardiomyocytes. We then examined whether full-length MURC/cavin-4 and ⌬CC affect Cav3 and PTRF/cavin-1 expression in cardiomyocytes. Full-length MURC/cavin-4 did Experiments were performed at least three times. Seventy-two hours after transfection, H9c2 cells were fixed, immunostained for caveolin-3 (Cav3), and then examined by fluorescence microscopy. Of note, on the right, Cav3 was localized at the plasma membrane in the adjacent H9c2 cell that had not been transduced with human ⌬CC-enhanced green fluorescent protein (EGFP), whereas it was not localized at the plasma membrane in the H9c2 cell expressing human ⌬CC-EGFP. Arrows highlight the localization of Cav3 at the plasma membrane. The exposure time to take the images of ⌬CC was longer than that of MURC/cavin-4. PEST, peptide sequence rich in proline (P), glutamic acid (E), serine (S), and threonine (T). Bar ϭ 20 m. B: immunoblot (IB) analysis of MURC-hemagglutinin (HA) and ⌬CC-HA. pcDNA3.1-hMURC-HA or pcDNA3.1-h⌬CC-HA was transfected into human embryonic kidney (HEK)-293 cells, and lysates were subjected to sucrose gradient analysis. Thirty micrograms of protein of the membrane fraction and 20 g protein of the cytosolic fraction were loaded for each well. Samples were assessed by IB analysis using anti-HA, anti-GAPDH, and anti-pan-cadherin antibodies. Fractionation experiments were performed at least three times. C: immunoprecipitation (IP) of Cav3 with full-length MURC/cavin-4 or ⌬CC. pcDNA3-mMURC-HA or pcDNA3-m⌬CC-HA was transfected with or without pcDNA3.1-hCav3-T7 into COS cells. Cell lysates were subjected to immunoprecipitation with the anti-HA or anti-T7 antibody. D: pulldown assay of Cav3 with MURC/cavin-4 or ⌬CC. pcDNA3-mMURC-FLAG or pcDNA3.1-m⌬CC-FLAG was transfected into COS cells. Cell lysates were incubated with glutathione-S-transferase (GST)-Cav3 fusion protein or GST alone. Pulldown samples were analyzed by probing with anti-FLAG and anti-GST antibodies. not affect only Cav3 and Ptrf/cavin-1 mRNA expression but also Cav3 and PTRF/cavin-1 protein levels in cardiomyocytes (Fig. 2, A and B) . ⌬CC also did not affect Cav3 and Ptrf/ cavin-1 mRNA expression in cardiomyocytes; however, it decreased the Cav3 protein level but not the PTRF/cavin-1 protein level in cardiomyocytes compared with LacZ and full-length MURC/cavin-4 (Fig. 2, A and B) . Cell fractionation experiments revealed that ⌬CC reduced the Cav3 protein level in the membrane fraction of cardiomyocytes compared with LacZ and that PTRF/cavin-1 protein expression did not differ among the membrane fractions of cardiomyocytes expressing LacZ, full-length MURC/cavin-4, and ⌬CC (Fig. 2C) .
Hypertrophic responses induced by ⌬CC in cardiomyocytes. We have previously shown that full-length MURC/cavin-4 induces cardiomyocyte hypertrophy (22) . To assess and compare physiological properties of full-length MURC/cavin-4 and ⌬CC, cardiomyocytes were transduced with Lac Z as a control, full-length MURC/cavin-4, or ⌬CC using recombinant adenoviruses, Ad-LacZ, Ad-MURC, and Ad-⌬CC. Forty-eight hours after infection with Ad-LacZ, Ad-MURC, and Ad-⌬CC, cardiomyocytes expressing full-length MURC/cavin-4 and ⌬CC showed increases in surface area compared with cardiomyocytes expressing LacZ (Fig. 3A) . Cardiomyocytes expressing ⌬CC showed higher hypertrophy-related fetal gene expression, such as ANP, BNP, and SkA mRNA expression, and higher a ␤-MHC-to-␣-MHC ratio than cardiomyocytes expressing fulllength MURC/cavin-4 (Fig. 3B) . Additionally, ⌬CC enhanced ERK activation in cardiomyocytes compared with full-length MURC/cavin-4 (Fig. 3C) . Thus, ⌬CC induced hypertrophic responses in cardiomyocytes.
Impaired cardiac function in ⌬CC-Tg mice. We next generated ⌬CC-Tg mice to examine the role of the coiled-coil domain in MURC/cavin-4 in vivo (Fig. 4A) . We made two lines (lines 1 and 2) of ⌬CC-Tg mice (Fig. 4B) . The cardiac expression level of the transgenic protein ⌬CC-FLAG was higher in line 2 of ⌬CC-Tg mice than in line 1. Therefore, we used line 2 of ⌬CC-Tg mice and compared them with sex-, strain-, and age-matched NTg control mice in the following experiments. We measured heart weights at 12-13 wk of age in NTg and ⌬CC-Tg mice ( Table 1 ). The heart weight-to-tibial length ratio in ⌬CC-Tg mice was significantly higher than that in NTg mice. In addition, lung weights, which were evaluated by lung weight-to-body weight and lung weight-to-tibial length ratios, in ⌬CC-Tg mice were also significantly higher than those in NTg mice. Cardiac sections of ⌬CC-Tg mice showed chamber dilatation compared with those of NTg mice (Fig.  4C) . Cross-sectional areas of cardiomyocytes and interstitial fibrosis increased in ⌬CC-Tg hearts compared with those in NTg hearts (Fig. 4, D and E) .
To address the functional consequences of ⌬CC expression in vivo, we performed echocardiography on NTg and ⌬CC-Tg mice at 12-13 wk of age. ⌬CC-Tg mice exhibited chamber dilatation and systolic dysfunction compared with NTg mice (Table 2) . Consistent with these observations, mRNA expression of ANP and BNP was elevated in ⌬CC-Tg hearts compared with NTg hearts (Fig. 4F) . Thus, ⌬CC-Tg mice showed severe cardiac dysfunction compared with NTg mice. These results suggest that nonmembrane-targeting MURC/cavin-4 affects cardiac function.
Reduced Cav3 protein expression in ⌬CC-Tg hearts. Because we have previously shown that full-length MURC/ cavin-4 overexpression induces dilatation of caveolae in car- diomyocytes (22), we then examined whether ⌬CC could influence the morphology of caveolae in cardiomyocytes. Transmission electron microscopy revealed that ⌬CC overexpression had no effect on the size or shape of caveolae in cardiomyocytes (Fig. 5A) . Immunostaining showed that anti-MURC/cavin-4 antibody-recognizing protein, which contains exogenous ⌬CC and endogenous MURC/cavin-4, was distributed to both the cytosol and plasma membrane of cardiomyocytes in ⌬CC-Tg mice (Fig. 5B) . Although immunostained Cav3 was detected at the plasma membrane of cardiomyocytes in ⌬CC-Tg mice, Western blot analysis revealed that the Cav3 Values are expressed as mean Ϯ SE; n ϭ 8 nontransgenic (NTg) mice and 3 transgenic mice expressing a muscle-restricted coiled-coil protein/cavin-4 mutant lacking the coiled-coil domain in the heart (⌬CC-Tg mice). *P Ͻ 0.05 compared with NTg mice; †P Ͻ 0.01 compared with NTg mice. protein level was decreased in ⌬CC-Tg hearts compared with NTg hearts (Fig. 5C) . The PTRF/cavin-1 protein level was similar between NTg and ⌬CC-Tg hearts. ERK activation was induced in hearts of ⌬CC-Tg mice compared with NTg mice (Fig. 5D) . These results suggest that impaired localization of MURC/cavin-4 reduces the number of caveolae in cardiomyocytes and the Cav3 protein level accompanying ERK activation in the heart.
DISCUSSION
In the present study, we demonstrated that deletion of the coiled-coil domain in MURC/cavin-4 impairs the proper localization of MURC/cavin-4 and reduces the Cav3 protein level at the plasma membrane of cardiomyocytes. ⌬CC induces ERK activation in cardiomyocytes. Furthermore, ⌬CC overexpression in the heart induces cardiac dysfunction accompanied by cardiomyocyte hypertrophy and interstitial fibrosis.
We have shown that MURC/cavin-4 is localized to caveolae of cardiomyocytes in the heart and is associated with other caveola-associated proteins, such as Cav3, PTRF/cavin-1, and SDPR/cavin-2, in cardiomyocytes (22, 23) . In the present study, we demonstrated that ⌬CC is distributed throughout the cytoplasm but is not localized at the plasma membrane of cardiomyocytes. Previous studies have shown that deletions of the coiled-coil domain in SDPR/cavin-2 and the leucine zipper domains in PTRF/cavin-1 and SRBC/cavin-3 impair their targeting to caveolae (8, 20, 34) . Furthermore, a minimal NH 2 -terminal domain, termed HR1, of zebrafish cavin-4a has been shown to be required for association with the lipid membrane (17) . Our findings also indicate that the coiled-coil domain in MURC/cavin-4 is essential for its membrane targeting in cardiomyocytes. We showed that ⌬CC is capable of binding to Cav3 in immunoprecipitation and GST experiments, which indicates that the function of the Cav-3-binding domain is retained in ⌬CC. ⌬CC decreased in Cav3 protein expression at the plasma membrane of cardiomyocytes, as shown in Figs. 1A and 2C, which also indicates that the coiled-coil domain in MURC/cavin-4 is required for Cav3 localization at the plasma membrane of cardiomyocytes. ⌬CC did not alter Cav3 mRNA expression in cardiomyocytes, whereas it decreased Cav3 protein levels in cardiomyocytes and ⌬CC-Tg hearts. These findings suggest that deletion of the coiled-coil domain in MURC/ cavin-4 impairs Cav3 trafficking to the plasma membrane of cardiomyocytes and that stability of the Cav3 protein is a prerequisite for its proper localization at the plasma membrane of cardiomyocytes. On the other hand, PTRF/cavin-1 protein levels were not altered by ⌬CC in cardiomyocytes, as shown in Fig. 2C, suggesting cavin-4 has different effects on the regulation of Cav3 and PTRF/cavin-1 in cardiomyocytes.
Cav3 regulates caveolar formation in cardiac and skeletal muscle cells, as shown in previous studies indicating that Cav3 deficiency leads to decreased numbers or the absence of caveolar structures in striated muscle and that Cav3 overexpression in cardiomyocytes increases the number of caveolae (5, 7, 15, 30, 35) . Although Cav3 protein levels were reduced in ⌬CC-Tg hearts and the membrane fraction of cardiomyocytes expressing ⌬CC, the size or shape of caveolae in cardiomyocytes was not affected in ⌬CC-Tg hearts, which implies that because endogenous MURC/cavin-4 protein is expressed in cardiomyocytes overexpressing ⌬CC, endogenous MURC/cavin-4 protein contributes to proper membrane localization and stabilization of Cav3 protein against ⌬CC actions and that the decreased Cav3 protein levels in ⌬CC-Tg hearts are insufficient to alter caveolar morphology. In Cav3 KO mice, Cav3 deficiency has been shown to induce ERK activation in the heart and cardiac hypertrophy, which results in impaired cardiac function (35) . We showed that ⌬CC overexpression in cardiomyocytes induces ERK activation and hypertrophic responses and that ⌬CC-Tg hearts showed ERK activation and cardiac dysfunction accompanying cardiomyocyte hypertrophy and interstitial fibrosis. Therefore, ⌬CC-induced reduction of Cav3 protein likely contributes to ERK activation and the development of cardiac dysfunction in ⌬CC-Tg mice.
In MURC/cavin-4-deficient cardiomyocytes, Cav3 is retained at the plasma membrane (22) . Moreover, MURC/cavin-4-deficient mice exhibit normal caveolar morphology and cardiac function under physiological conditions, whereas upon ␣ 1 -adrenergic receptor stimulation, MURC/cavin-4-deficient mice show attenuation of cardiac hypertrophy accompanied by suppressed ERK activation (22) . On the other hand, ⌬CC leads to Cav3 reduction and ERK activation in cardiomyocytes despite the absence of ⌬CC at the plasma membrane. As a consequence, ⌬CC-Tg mice exhibit cardiac dysfunction. These findings suggest that MURC/cavin-4 at the caveolae is necessary to elicit efficient signaling of the ␣ 1 -adrenergic receptor/ ERK cascade, whereas cytoplasmic MURC/cavin-4 mislocalization causes alterations of caveola-associated proteins and signaling in cardiomyocytes, which result in cardiac dysfunction. Thus, MURC/cavin-4 works as a critical caveolar component in cardiomyocytes.
As shown in the present study, deletion of the coiled-coil domain in MURC/cavin-4 impairs the localization of MURC/ cavin-4 in cardiomyocytes and causes decreases in Cav3 protein level at the plasma membrane accompanied by ERK activation, which results in cardiac dysfunction. These findings indicate the critical roles of MURC/cavin-4 as a caveolar component in cardiomyocytes and provide insights into molecular mechanisms underlying caveola-mediated signaling in cardiac function.
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